Progression-free survival was improved in patients with ER+ versus ER− disease, and the highest objective response was in ER+ patients with luminal intrinsic subtype.
A sizeable fraction of breast cancers are both ER+ and HER2+. Given the improvement in outcomes for patients with advanced ER+ disease receiving endocrine therapy combined with CDK4/6 inhibitors as well as for patients with HER2+ disease with several new HER2-targeted agents, it begs the question of whether combining these therapeutic strategies in patients with both HER2+ and ER+ disease is feasible and clinically advantageous.
Now, the Spanish cooperative group (SOLTI) has conducted a prospective, multicenter, open-label, randomized, phase 2 study (PATRICIA SOLTI-1303) to evaluate the combination of the CDK4/6 inhibitor palbociclib with trastuzumab, with or without endocrine therapy, in 71 postmenopausal patients with unresectable, advance…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)